公开(公告)号：US20240247266A1

公开(公告)日：2024-07-25

申请号：US18542950

申请日：2023-12-18

申请人： Alnylam Pharmaceuticals, Inc.

发明人： Stephen Albert Huang ,  Kenji P. Fujita ,  Kang Lin ,  Nitin Mehrotra ,  Gabriel Robbie ,  Jongtae Lee ,  Sagar Agarwal

IPC分类号： C12N15/113 ,  A61K31/4184 ,  A61K31/713 ,  A61P9/12

CPC分类号： C12N15/1136 ,  A61K31/4184 ,  A61K31/713 ,  A61P9/12 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/323 ,  C12N2310/33 ,  C12N2310/351

摘要： The present invention relates to methods of inhibiting the expression of an AGT gene in a subject, as well as methods for treating subjects having an AGT-associated disorder, e.g., hypertension, using RNAi agents, e.g., double stranded RNAi agents, targeting the AGT gene. The invention also relates to methods of decreasing blood pressure levels in a subject using such RNAi agents to inhibit expression of an AGT gene.